- Home
- MREO vs CLNN Comparison
MREO vs CLNN Comparison
Compare MREO & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | CLNN |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 57.4M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MREO | CLNN |
|---|---|---|
| Price | $0.34 | $3.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $1.96 | ★ $32.20 |
| AVG Volume (30 Days) | ★ 1.7M | 121.9K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,000.00 | $200,000.00 |
| Revenue This Year | N/A | $24.70 |
| Revenue Next Year | N/A | $9,228.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.20 | $3.25 |
| 52 Week High | $2.37 | $13.50 |
Technical Indicators
Market Signals| Indicator | MREO | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 42.32 |
| Support Level | $0.35 | $3.25 |
| Resistance Level | $0.35 | $4.70 |
| Average True Range (ATR) | 0.04 | 0.27 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 47.31 | 15.16 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.